- Home
- RANI vs HKPD Comparison
RANI vs HKPD Comparison
Compare RANI & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RANI
- HKPD
- Stock Information
- Founded
- RANI 2012
- HKPD 2016
- Country
- RANI United States
- HKPD Hong Kong
- Employees
- RANI N/A
- HKPD N/A
- Industry
- RANI Medicinal Chemicals and Botanical Products
- HKPD Other Pharmaceuticals
- Sector
- RANI Health Care
- HKPD Health Care
- Exchange
- RANI Nasdaq
- HKPD Nasdaq
- Market Cap
- RANI 19.6M
- HKPD 20.9M
- IPO Year
- RANI 2021
- HKPD 2025
- Fundamental
- Price
- RANI $0.50
- HKPD $1.54
- Analyst Decision
- RANI Strong Buy
- HKPD
- Analyst Count
- RANI 4
- HKPD 0
- Target Price
- RANI $7.75
- HKPD N/A
- AVG Volume (30 Days)
- RANI 317.2K
- HKPD 3.3M
- Earning Date
- RANI 08-05-2025
- HKPD 01-01-0001
- Dividend Yield
- RANI N/A
- HKPD N/A
- EPS Growth
- RANI N/A
- HKPD N/A
- EPS
- RANI N/A
- HKPD 0.21
- Revenue
- RANI $1,200,000.00
- HKPD $20,770,344.00
- Revenue This Year
- RANI N/A
- HKPD N/A
- Revenue Next Year
- RANI N/A
- HKPD N/A
- P/E Ratio
- RANI N/A
- HKPD $7.21
- Revenue Growth
- RANI N/A
- HKPD 32.91
- 52 Week Low
- RANI $0.46
- HKPD $0.81
- 52 Week High
- RANI $4.37
- HKPD $3.79
- Technical
- Relative Strength Index (RSI)
- RANI 29.91
- HKPD N/A
- Support Level
- RANI $0.51
- HKPD N/A
- Resistance Level
- RANI $0.56
- HKPD N/A
- Average True Range (ATR)
- RANI 0.04
- HKPD 0.00
- MACD
- RANI 0.01
- HKPD 0.00
- Stochastic Oscillator
- RANI 0.38
- HKPD 0.00
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.